Joseph Merriman, MD, Oncology, Nashville, TN, Vanderbilt University Medical Center

JosephMerrimanMD

Oncology Nashville, TN

Genitourinary Oncology, Hematologic Oncology, Melanoma

MD at Vanderbilt

Dr. Merriman is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Merriman's full profile

Already have an account?

Education & Training

  • University of Utah
    University of UtahRESIDENCY
  • University of Tennessee College of Medicine
    University of Tennessee College of MedicineMEDICAL_SCHOOL
  • Sewanee: The University of the SouthOTHER_TRAINING
  • University of The SouthOTHER_TRAINING
  • Vanderbilt University
    Vanderbilt UniversityFELLOWSHIP

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2019 - 2020
  • TN State Medical License
    TN State Medical License 2017 - 2020
  • UT State Medical License
    UT State Medical License 2014 - 2018
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Oncology Trainee Award ASCO Conquer Cancer Foundation, 2014
  • Imhotep Honors Society University of Tennessee School of Medicine, 2013
  • Tennessee Scholarship Award University of Tennessee School of Medicine, 2009
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Neutrophil-lypmhocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patient with renal cell carcinoma  
    Kuzman, JA, Stenehjem, DD, Merriman, J, Agarwal, AM, Patel, SB, Hahn, AW, Alex, A, Albertson, D, Gill, DM, Agarwal, N, BMC Urology, 1/1/2017
  • Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular en...  
    Bailey EB, Merriman J, Maughan B, et al, Journal of Oncology Pharmacy Practice, 1/1/2017
  • Extension of overall survival beyond objective responses in patient with metastatic renal cell carcinoma treated with high-dose interleukin-2  
    Stenehjem, DD, Toole, M, Merriman, J, Parikh, K, Daignault, S, Scarlett, S, Esper, P, Skinner, K, Udager, A, Tantravahi, SK, Gill, D, Straubhar, AM, Agarwal, AM, Gross..., Cancer Immunology and Immunotherapy, 1/1/2016
  • Join now to see all

Abstracts/Posters

  • Breast cancer risk assessment and chemoprevention use among VA primary care.
    Merriman J, Bidassie B, Kovach A, Vallette M, Park YHA, Aggarwal A, Colonna S, American Society of Clinical Oncology annual meeting, Chicago, IL, 1/1/2017
  • Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (...
    Stenehjem DD, Toole M, Merriman J, Parikh K, Daignuault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Samlowski WE,..., American Society of Clinical Oncology annual meeting, Chicago, IL, 1/1/2015
  • Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with h...
    Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal AM, Sendilnathan A, Van Atta J, Batten JA, Grossmann KF, Samlowski WE, Stenehjem DD, Agarwal N, American Society of Clinical Oncology annual meeting, Chicago, IL, 1/1/2014

Professional Memberships

Hospital Affiliations